Thursday, June 30, 2016

Roth starts Heat Biologics at buy

Roth starts Heat Biologics at buy

June 20, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and $2.75 price target. The stock closed at 60 cents on Friday. “Heat Biologics possesses a portfolio of unique, differentiated vaccines that, in our opinion, could bring a much needed boost to the cancer vaccine space, which has been plagued […]

Roth starts PhaseRx at buy

Roth starts PhaseRx at buy

June 17, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of PhaseRx (NASDAQ:PZRX) with a “buy” rating and 12-month price target of $8. The stock closed at $5 on Thursday. “In our opinion, PhaseRx’s technology platform, combined with promising preclinical results, first mover advantage in the multi-billion dollar i-ERT market opportunity, a number of potential upcoming milestones, and […]

Roth starts Capricor Therapeutics at buy

Roth starts Capricor Therapeutics at buy

June 15, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has launched coverage of Capricor Therapeutics (NASDAQ:CAPR) with a “buy” rating and $12 price target. The stock closed at $4.17, up 63 cents, on Wednesday. “We believe Capricor is a stem cell player poised for a major leadership role in the treatment of cardiovascular disease,” writes analyst Joseph Pantginis. “Supporting this […]

Roth reinitiates coverage of Cempra at buy

Roth reinitiates coverage of Cempra at buy

June 7, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has reinitiated coverage of Cempra (NASDAQ:CEMP) with a “buy” rating and $37 price target. The stock closed at $19.48 on Monday. “With impressive pivotal studies on solithromycin (Solitaire-IV and Solitaire-Oral), we encourage investors to accumulate a position in Cempra as the company leverages its clinical data in treating community acquired bacterial […]

Roth starts Biocept at buy

Roth starts Biocept at buy

June 7, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage on Biocept (NASDAQ:BIOC) with a “buy” rating and target price of $1.20. The stock closed at 63 cents on Monday. “Through its proprietary technology platform capable of assaying both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), strong IP portfolio, notable collaborations with leading cancer institutions, and […]

Roth ups Titan Pharma price target to $10

Roth ups Titan Pharma price target to $10

May 30, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for Titan Pharmaceuticals (NASDAQ:TTNP) to $10 from $7.75 after the FDA approved Titan’s six-month Probuphine implant for the treatment of opioid addiction. The stock closed at $7.07 on Friday. “The hook here is forced compliance,” writes analyst Scott Henry. “The implant removes the risk of noncompliant […]

Roth resumes coverage of Fibrocell at buy

Roth resumes coverage of Fibrocell at buy

May 24, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has resumed coverage of Fibrocell Science (NASDAQ:FCSC) with a “buy” rating and $7 price target. The stock closed at $2.12 on Monday. Fibrocell leverages its expertise with fibroblasts to target diseases of the skin, connective tissue and joints. The technology can take advantage of the inherent properties of fibroblasts, but also […]

Roth adjusts DelMar Pharma price target to $12

Roth adjusts DelMar Pharma price target to $12

May 23, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has adjusted its price target for DelMar Pharmaceuticals (OTCQX:DMPID) to $12 from $3 after the company’s 1-for-4 reverse stock split. The stock closed at $5.41 on Friday. Analyst Joseph Pantginis writes that the company’s net equity and operating funds are now sufficient to meet the goal of up listing to a […]

Roth ups Celator Pharma price target to $26

Roth ups Celator Pharma price target to $26

May 19, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for Celator Pharmaceuticals (NASDAQ:CPXX) to $26 from $22, after the company’s Vyxeos drug candidate received breakthrough therapy designation from the FDA. The stock closed at $15.07 on Wednesday “This is an important next step for Vyxeos on the path to what we believe is likely approval,” […]

Roth reinitiates coverage of NeoGenomics at buy

Roth reinitiates coverage of NeoGenomics at buy

May 11, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has reinitiated coverage on NeoGenomics with a “buy” rating and target price of $10, following its acquisition of Clarient from GE Healthcare. The stock closed at $8.34 on Tuesday. “We believe NeoGenomics is on the brink of demonstrating significant sales growth and operating leverage over the next several years as the […]

Next Page »

Email Newsletters with Constant Contact
Google+